[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pseudoexfoliation-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pseudoexfoliation-glaucoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,52,88,109,134,156,190,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100640261","phase-1-topical-insulin-for-glaucoma-ting2-100640261",false,"NCT07619482","Topical Insulin for Glaucoma (TING2)","A Phase 1\u002F2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma","Limited Inclusion Criteria - All Groups:\n\n* Provide written informed consent approved by the appropriate ethics committee\n* Age 18 years or older\n* Understand study procedures and have the ability and willingness to abide by all procedures during the study\n* Capable of providing informed consent\n* Diagnosis of glaucoma\n* Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and\u002For visual field will be selected\n\nLimited Exclusion Criteria - All Groups:\n\n* Pregnant or breastfeeding\n* Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus\n* Inability to perform reliable visual field testing\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study","ALL","18 Years","90 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1\u002F2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.",[28,29,30,31,32],"Open Angle Glaucoma","Primary Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[34,35,36,37,38],"glaucoma","neuroprotection","topical insulin","retinal ganglion cell","EYED-002","NOT_YET_RECRUITING","2026-05-26",{"date":42,"type":43},"2026-06-02","ACTUAL",{"date":45,"type":21},"2026-06",{"date":47,"type":21},"2029-10",{"name":49,"class":50},"Stanford University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":51},"100568571","transcorneal-electrical-stimulation-for-the-treatment-of-visual-field-defects-in-patients-with-open-angle-glaucoma-100568571","NCT06682962","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma - a Monocentric, Randomized, Double-Masked, Sham-Controlled Pilot Study","TES-GPS","Inclusion Criteria:\n\n1. Willingness to participate in the study, the subjects signed and dated informed consent must be submitted before the start of the screening\n2. Age ≥ 40 years\n3. Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma (according to the EGS criteria) in the study eye\n4. Current progression in perimetry of at least 1.5 dB per year in the study eye and mean defect (MD) in the study eye between ≥ 6 and ≤ 12 dB (Octopus visual field) or ≤ -6 and ≥ -12 dB (Humphrey visual field) in the screening examination as the mean value of the two visual field examinations carried out as part of the screening (permitted deviation maximum 2 dB)\n5. Visual acuity ≥ 0.2 decimal in the study eye (corresponds to a visual acuity of 0.7 logMAR)\n6. The patient must master home stimulation after extensive training.\n7. Ability of subject to understand the scope, significance and individual consequences of participation in the study\n8. Ability of subject to give consent\n9. If both eyes meet the inclusion\u002Fexclusion criteria, the eye with the higher MD is selected as the study eye. If the MD is the same in both eyes, the eye with the worse visual acuity will be selected as the study eye. If there is no difference between the eyes, the right eye will be selected as the study eye\n10. Negative serum or urine pregnancy test at screening in women of childbearing potential. Participants are considered to be of nonchildbearing potential if they are postmenopausal and have not menstruated for at least 12 months prior to screening or if they are surgically sterile\n11. Women of childbearing potential must agree to be abstinent or to use highly effective methods of contraception that result in a failure rate of less than 1% per year. This applies consistently throughout the duration of the treatment once you have given your consent to participate in the study.\n\nExclusion Criteria:\n\n1. Neovascularisations of any origin in the study eye\n2. Condition after arterial or venous occlusions in the study eye\n3. Condition after intraocular surgery in the last 3 months before the screening examination in the study eye\n4. Acute (intra)ocular inflammation in any eye\n5. Non-proliferative or proliferative diabetic retinopathy in the study eye\n6. Condition after retinal detachment in the study eye\n7. Dry age-related macular degeneration affecting the visual field in the study eye\n8. Exsudative age-related macular degeneration in the study eye\n9. Macular edema of any origin in the study eye\n10. Other relevant retinal diseases in the study eye\n11. Any form of corneal degeneration that limits vision in the study eye\n12. Any disease other than glaucoma affecting the central 30° visual field in the study eye\n13. No cataract surgery or other eye surgery may be planned for the patient in the study eye during the duration of the study (except laser trabeculoplasty)\n14. Patients with active implants\n15. General illnesses that are difficult to control\u002Fadjust and which, in the opinion of the investigator, could jeopardize regular study routines\n16. Poor general condition according to the investigators assessment\n17. Mental illness or dementia, that, in the opinion of the investigator, reduces the understanding of the study procedures and use of the Okustim 2 System\n18. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days)\n19. Breastfeeding women\n20. Patients unable to consent\n21. Previous enrolment in the TES-GPS study\n22. Contraindications to the use of OkuStim 2 such as allergies\u002Fhypersensitivity to silver","40 Years",{"count":62,"type":21},50,[64],"NA","Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.\n\nThe aim of this pilot study is to evaluate the safety and effectiveness of the treatment of visual field defects using transcorneal electrical stimulation (TES) with the OkuStim 2 System in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma.",[67,29,32,68,69],"Glaucoma","Pigment Dispersion Glaucoma","Normal Tension Glaucoma",[71,72,73,74,75,67,76],"TES","TcES","POAG","OkuStim","Okuvision","Electrical Stimulation","RECRUITING","2026-03-10",{"date":80,"type":43},"2026-03-12",{"date":82,"type":43},"2025-04-02",{"date":84,"type":21},"2028-06",{"name":86,"class":87},"Okuvision GmbH","INDUSTRY",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100623796","the-safety-and-efficacy-of-direct-slt-in-pseudoexfoliation-glaucoma-100623796","NCT07401290","The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma","Inclusion Criteria:\n\n* Adult patients diagnosed with pseudoexfoliation glaucoma (PXFG), with optic neuropathy consistent with glaucomatous damage of any severity\n* Open iridocorneal angle by gonioscopy, defined as a Shafer Grade II or greater\n* Treatment naive, or washed out IOP ranging from ≥18-35 mmHg\n* Able to complete medication washout safely and all follow-up visits\n* Participants must have a best correct visual acuity of 20\u002F40 or better in the study eye(s), be able to undertake a reliable Humphrey visual field (HVF) (defined as fixation losses, false positives and false negatives less than 33%), and must have field loss no worse than -20 dB in treatment eye\n\nExclusion Criteria:\n\n* Any contraindication to SLT or unable to have DSLT\n* Angle closure glaucoma or any other types of glaucoma other than PXFG\n* Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye\n* Any prior refractive surgery\n* H\u002Fo LPI within last 6 months\n* A history of any significant cataract required during study duration or cataract surgery in the last 6 months\n* Prior laser trabeculoplasty (ALT\u002FSLT)\n* History of ocular inflammation and infection\n* Patients who are pregnant or have any clinically relevant systemic disease that may prevent them from reliably completing follow-up visits\n* Vulnerable populations that cannot provide proper informed consent will not be enrolled, such as children, prisoners, handicapped, or mentally disabled persons, or economically or educationally disadvantaged persons",{"count":95,"type":21},40,[64],"Prospective, multi-center, single arm, interventional study evaluating DSLT in patients with pseudoexfoliative glaucoma.",[32],"2026-02-03",{"date":101,"type":43},"2026-02-10",{"date":103,"type":21},"2026-03",{"date":105,"type":21},"2028-03",{"name":107,"class":50},"Vance Thompson Vision",3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":73,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":51},"100610487","phase-4-standalone-istent-infinite-and-idose-tr-for-management-of-moderate-to-severe-open-angle-glaucoma-100610487","NCT07228221","Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma","iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)","Inclusion Criteria:\n\n* Moderate to severe open angle glaucoma (including POAG, PG, and PXG)\n* Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9\n* Visual acuity HM or better\n* VF MD -6dB or worse\n* Failed medical therapy and\u002For laser treatment\n* Incisional glaucoma surgery contemplated as next intervention\n* Phakic or pseudophakic\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma\n* Previous incisional glaucoma surgery\n* ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days\n* Active ocular inflammation or edema, clinically significant corneal dystrophy\n* Corneal or other pathology preventing accurate Goldmann applanation tonometry",{"count":117,"type":21},20,[119],"PHASE4","The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.",[28,31,32],[73,123,124],"PG","PXG","2025-11-13",{"date":127,"type":43},"2025-11-14",{"date":129,"type":21},"2026-01-05",{"date":131,"type":21},"2031-12-31",{"name":133,"class":50},"Jonathon Myers",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":51},"100472997","xen-glaucoma-gel-stent-versus-trabeculectomy-100472997","NCT05439161","XEN Glaucoma Gel Stent Versus Trabeculectomy","Multicentric Evaluation of Best Corrected Visual Acuity of the XEN Implant Versus Classic Trabeculectomy in Open Angle Glaucoma Subjects","Inclusion Criteria:\n\n1. Diagnosis of open angle glaucoma (Primary open angle glaucoma, Pseudoexfoliation glaucoma, Pigmentary dispersion glaucoma)\n2. Clinically eligible for both surgeries (Trabeculectomy and XEN) on the discretion of the surgeon (area of healthy, free and mobile conjunctiva in the superior nasal target quadrant)\n3. VA logMAR ≤ 1 (VA dec ≥ 0.1)\n4. Trabecular meshwork must be visible (with Shaffer angle grade \\> 1 in the target quadrant)\n5. Age 18 years or older\n6. Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent\n\nExclusion Criteria:\n\n1. Clinical significant cataract\n2. Subject has had prior cataract surgery in study eye ≤ 1 months (count to operation)\n3. Subject has had prior (incisional) glaucoma surgery (XEN, trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.). Prior iridotomy is acceptable.\n4. Phacic Angle Closure Glaucoma\n5. Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders\n6. Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)\n7. Anterior chamber intraocular lens\n8. Vitreous present in the anterior chamber\n9. Presence of intraocular silicone oil\n10. History of corneal surgery, corneal opacities, or corneal disease\n11. Impaired episcleral venous drainage (e.g. Sturge-Weber or nanophthalmos)\n12. History of dermatologic keloid formation\n13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, or other ophthalmic disease or disorder that could confound study results\n14. Known or suspected allergy or sensitivity to drugs required for the surgical procedure or any of the device components (e.g., porcine products or glutaraldehyde),\n15. Pregnant or nursing women",{"count":142,"type":21},196,[64],"Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects",[29,32,146],"Pigmentary Dispersion Glaucoma","2025-05-28",{"date":149,"type":43},"2025-06-03",{"date":151,"type":43},"2023-12-20",{"date":153,"type":21},"2026-09-30",{"name":155,"class":50},"Prof. Dr. Herbert Reitsamer",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100584168","vitamin-mix-b6-b9-b12-and-choline-for-glaucoma-patients-100584168","NCT06885827","Vitamin Mix (B6, B9, B12, And Choline) For Glaucoma Patients","Interventional Vitamin Mix Glaucoma Study (IVMGS) - A Prospective, Randomized, Two-Arm, Single-Center Study Protocol in Existing Glaucoma Patients.","IVMGS","Eligibility Criteria\n\nInclusion Criteria:\n\nPatients with the following characteristics will be eligible for inclusion in the trial:\n\n* 18 years or older at the time of inclusion\n* Diagnosis of Primary Open-Angle Glaucoma (POAG), Normal Tension-Glaucoma (NTG) or Pseudoexfoliation Glaucoma (PEXG) in one or both eyes diagnosticed by an ophthalmologist.\n* Best corrected Snellen VA of 0.3 or better in the study eye(s)\n* Two or more reliable VF tests with less than 15% false positives\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from participation in the study:\n\n* Visual field damage worse than -16dB in the study eye(s)\n* Eye pressure greater than 35 mmHg in study eye(s) on either of two measurement occasions or a mean pressure of 30 mmHg over two occasions\n* Any disease affecting retinal function\n* Neurological or other non-glaucomatous conditions that may affect the visual field\n* Inability to perform visual field examination\n* Unwillingness to stop any intake of multivitamins or B vitamin substances\n* Known allergy or intolerance to B-vitamins\n* Previous eye surgery, except for uncomplicated cataract surgery\n* Pregnant or breastfeeding women\n* Women of childbearing potential who do not use reliable contraception\n* Any disease or condition likely to prevent long-term follow-up\n* Cancer diagnosis within the last 5 years (except treated squamous cell carcinoma)\n* History of liver disease or stomach ulcers\n* Inability to understand and speak Swedish or English",{"count":165,"type":21},80,[64],"This study aims to determine whether a combination of vitamins (B6, B9, B12, and choline) can help protect the eyes of people with glaucoma and slow vision loss. The study will assess whether these vitamins support retinal cells and maintain or improve their function.\n\nAdults aged 18 and older with primary open-angle glaucoma (including normal-tension glaucoma) or pseudoexfoliation glaucoma, and those with mild to moderate glaucoma, may be eligible. Participants must meet specific medical criteria and cannot take additional vitamin supplements during the study.\n\nParticipants will be randomly assigned to one of two groups: one group will take a daily vitamin supplement (B6, B9, B12, and choline) for one year, along with standard glaucoma care, while the other will continue standard care without extra vitamins. The vitamins used are well tolerated at selected doses, with possible mild side effects such as an upset stomach or tingling sensations. They will visit the clinic five times over 12 months (at the start, and at 3, 6, 9, and 12 months) for routine eye tests, including measuring eye pressure, checking vision and visual fields, taking scans of the eye's nerve layers (OCT), and completing an electroretinogram (ERG) to assess retinal function. Blood samples will also be collected.\n\nIf the vitamins are effective, this could provide an additional strategy alongside current eye pressure lowering treatments to reduce vision loss.",[169,32],"Open-angle Glaucoma",[171,34,35,172,173,174,175,176,177,178,179],"methyl donor supplementation","randomized clinical trial","open-label","B6","B9","choline","visual field","optical coherence tomography","electroretinogram","2025-04-25",{"date":182,"type":43},"2025-04-29",{"date":184,"type":43},"2025-03-31",{"date":186,"type":21},"2027-03-31",{"name":188,"class":50},"Karolinska Institutet",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":51},"100556334","trabeculopuncture-as-predictive-test-for-the-success-of-ab-interno-trabeculectomy-100556334","NCT06523751","Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy","Determining Distal Outflow Tract Function in Open Angle Glaucoma as a Predictive Test for the Success of Ab Interno Trabeculectomy","Inclusion Criteria:\n\n* individuals ≥ 18 years of age\n* clinical diagnosis of: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma\n* uncontrolled intraocular pressure (IOP) with maximally tolerated medical therapy\n* progressive thinning of retinal nerve fiber layer assessed by Spectral domain optical coherence tomography (p \\\u003C 0.05)\n* progression of visual field defects\n* visually significant cataract and indication to reduce IOP or glaucoma medication burden\n\nExclusion Criteria:\n\n* clinical diagnosis of neovascular glaucoma, angle-closure glaucoma, uveitic glaucoma, neovascular glaucoma\n* prior glaucoma surgery\n* preexisting conditions affecting the episcleral venous pressure including Grave's ophthalmopathy, Sturge-Weber syndrome, Arteriovenous fistulas (carotid-cavernous fistula)",{"count":198,"type":21},55,[64],"The purpose of this study is to perform trabeculopuncture a test to determine the distal outflow tract function to predict the success of ab interno trabeculectomy.",[28,32],[203,204,28],"Ab Interno Trabeculectomy","Trabeculopuncture",{"date":206,"type":43},"2025-04-03",{"date":208,"type":43},"2023-06-13",{"date":210,"type":21},"2026-01-31",{"name":212,"class":50},"Wuerzburg University Hospital",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":51},"100394489","phacoemulsification-vs-slt-as-initial-treatment-for-pseudoexfoliation-glaucoma-100394489","NCT04416724","Phacoemulsification vs SLT as Initial Treatment for Pseudoexfoliation Glaucoma","Canadian Pseudoexfoliation Glaucoma Trial: Comparison of Phacoemulsification Versus Selective Laser Trabeculoplasty as Initial Treatment for Pseudoexfoliation Glaucoma","CANPEX1","Inclusion Criteria:\n\n1. Pseudoexfoliation syndrome, detected at slit-lamp examination by exfoliative material on anterior capsule, pupil, or anterior chamber angle\n2. Clinical decision to lower the IOP, as assessed by the investigator who is treating the subject, based on the presence of PXG or with IOP elevated enough to warrant treatment, even without clear evidence of optic nerve damage or visual field defect\n3. Presence of asymptomatic early cataract\n\nExclusion Criteria:\n\n1. Age less than 50 years old\n2. Anterior chamber angle closure at gonioscopy, defined as pigmented trabeculum visible in less than 180º\n3. Previous IOP lowering procedure such as trabeculoplasty, trabeculectomy, or minimally invasive glaucoma surgery\n4. Previous use of IOP lowering medication for more than 6 months\n5. Presence of ocular or systemic pathology or medication that could significantly influence the IOP, such as: uveitis, neovascular or traumatic glaucoma, corneal pathology influencing tonometry, use of oral steroids\n6. IOP at baseline visit higher than 36 mmHg\n7. Visual field damage at baseline visit with mean deviation worse than -15 dB\n8. Not able or willing to provide voluntary, informed consent to participate in the study","50 Years",{"count":223,"type":21},200,[64],"The Canadian Pseudoexfoliation Glaucoma Study 1 is a randomized clinical trial that aims to compare two initial treatment options - Selective Laser Trabeculoplasty (SLT) and Phacoemulsification (PHACO) - in newly diagnosed patients with pseudoexfoliation and need to lower the intraocular pressure. Patients with pseudoexfoliation and a recent decision to lower the intraocular pressure, who also have early asymptomatic lens opacification will be recruited and randomized to receive either SLT or PHACO. Patients will be followed for 2 years according to a target IOP protocol based on the Canadian Ophthalmological Society Glaucoma guidelines. Patients who do not achieve the target IOP with the initial randomization procedure will receive IOP lowering medications. The main outcome of interest will be the proportion of subjects who need IOP lowering medications after 2 years. Secondary outcomes include IOP reduction, time to need medications, patient reported outcomes in terms of visual function, and occurrence of adverse effects. To obtain longer follow-up information beyond two years, a chart review will be done 5 and 10 years after randomization.",[32],"2024-08-19",{"date":229,"type":43},"2024-08-21",{"date":231,"type":43},"2022-10-10",{"date":233,"type":21},"2033-08",{"name":235,"class":50},"Nova Scotia Health Authority"]